Future Oncology
New MEdicine Inc, May 2013
Future Oncology is an analytical newsletter for executives, researchers, and market analysts in the pharmaceutical, biotechnology, financial, hospital and other health care industries. It provides comprehensive, up-to-date analysis of scientific, technological, clinical and commercial developments in oncology.
Topics Covered in Future Oncology:
Epidemiology
Worldwide (North America, Europe, Japan, etc.) mortality and incidence estimates by gender, cancer subtype and stage; estimates of populations carrying certain markers and under treatment by type of therapy.
Mechanism in Malignancy
Etiology, pathogenesis and markers by type of cancer; exploitation of mechanisms of malignancy (apoptosis, angiogenesis, cell cycle regulation, multi-drug resistance, etc.) in screening, diagnosis, disease monitoring, prognosis and drug development, including databases of agents in development.
Technology Updates
Technological advances such as in vivo and ex vivo gene therapy using a variety of vectors and delivery approaches, monoclonal antibodies in diagnosis and therapy, radiopharmaceuticals, photodynamic therapy, immunotherapy/vaccines, hematopoietic support, and many more.
Drugs in Development, Markets and Developers
Profile of major oncology drug classes (taxanes, topoisomerase I inhibitors, platinum-based drugs, cell cycle regulators, etc.), estimated worldwide markets for commercialized drugs, descriptions of oncology-related operations of various commercial entities, including their affiliations.
Conference Coverage
Coverage of meetings in the cancer and related fields such as the International Congress on Anti-Cancer Chemotherapy (ICACC); International Conference on Monoclonal Antibody Immunoconjugates for Cancer; Annual Meeting of the American Association for Cancer Research (AACR); Digestive Disease Week; Annual Session of the American Society of Clinical Oncology (ASCO); Annual Meeting of the Society of Nuclear Medicine; International Congress of Chemotherapy; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); and many more.
Example of topics covered in this publication include:
THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr) PATHWAY IN CANCER
PART II - TARGET CANCER INDICATIONS AND TARGETING APPROACHES
ErbB RECEPTORS ASSOCIATION BY CANCER INDICATION
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr)
-Colorectal Cancer
-Head and Neck Cancer
-Lung Cancer
-Prostate Cancer
-Ovarian Cancer
-Brain Cancer
-Breast Cancer
-Pancreatic Cancer
HEr2/neu (HEr2, ErbB2)
-Breast Cancer
-Ovarian Cancer
-Pancreatic Cancer
-Osteosarcoma
-Lung Cancer
-Other Malignancies
-HEr3 (ErbB3)
-HEr4 (ErbB4)
-EGFr VARIANT III (EGFrvIII
TARGETING ErbB RECEPTORS FOR THE TREATMENT OF CANCER
-INTRACELLULAR TARGETING
-Reversible and Irreversible Inhibitors
-Specific, Dual, and Pan-ErbB Inhibitors
-EXTRACELLULAR TARGETING
-Naked Monoclonal Antibodies (MAb)
-Bispecific MAb
-Immunoconjugates
-IMMUNOTHERAPIES/VACCINES USING ErbB AS ANTIGENS
MECHANISMS OF RESISTANCE AND TOXICITY
-RESISTANCE
-TOXICITY
MEETING COVERAGE
NEW TARGETS AND DELIVERY SYSTEMS
IN CANCER DIAGNOSIS AND TREATMENT
FROM THE MARCH 2007 CONFERENCE ORGANIZED
BY THE SIDNEY KIMMEL CANCER CENTER IN SAN DIEGO, CA
ADOPTIVE IMMUNOTHERAPY (AI)
-Adoptive Transfer of IL-2-activated Natural Killer (NK) Cells
NOVEL DRUG DELIVERY FOR TUMOR TARGETING AND IMAGING
-Biologic Agents as Delivery Vehicles
-Cytokine-induced killer (CIK) Cells
-Nanotechnology
INTEGRATING MOLECULAR TARGETS AND BIOMARKERS
-Correlation of Apoptosis, p53, and Mitochondria
TARGETING THE TUMOR MICROENVIRONMENT
-Vaccines
-Legumain-based vaccines
-Prodrugs
-Peritumoral Acinar Tissue Imaging
IMAGING OF TUMORS
-Proteomic Mapping and Imaging
-Imaging of Signal Transduction Pathways
-Imaging of Tumors/Microenvironment
-Monitoring of Cyclooxygenase-2 (Cox-2) to Assess Tumor Progression VECTORS
-Pancreatic Cancer-specific Vector
-Breast Cancer-specific Vector
-Endostatin Prodrug
-Viral-based Therapy for Multiple Myeloma
-Targeted adn Shielded Adenovirus Vectors
-Whole Cell Vaccines for Acute Myeloid Leukemia (AML)
-Replication-competent Retroviral (RCR) Vectors
LIST OF EXHIBITS
Exhibit 1 - Potential Treatment Implication(s) of Selected Related EGFr Pathway Mutations
Exhibit 2 - EGFr Family Member Expression Rates (%) in Human Malignancies
Exhibit 3 - Epidermal Growth Factor (EGF) Receptor (EGFr) in Malignancy
Exhibit 4 - HEr2/neu (Her-2/neu) in Malignancy
Exhibit 5 - ErbB3 in Malignancy
Exhibit 6 - ErbB4 in Malignancy
Exhibit 7 - Epidermal Growth Factor Receptor Variant III (EGFrvIII) in Malignancy
Exhibit 8 - Selected EGFr Family Small Molecule Tyrosine Kinase Inhibitors (TKI)
Exhibit 9 - Selected ErbB Receptor-Based Immunotherapies/Vaccine Approaches
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
